Korea’s Dong-A Pharmaceutical Inks JV To Build Plant In Mongolia
This article was originally published in PharmAsia News
Executive Summary
Struggling from a recent indictment of over rebates, Korea’s leading pharma seeks new momentum in one of the most sparsely populated countries in the world.
You may also be interested in...
Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
Korea Allows Sales Of OTC Products In Supermarkets July 21, But Distribution Remains A Challenge
SEOUL - South Koreans are expected to be able to purchase 48 new over-the-counter products at supermarkets and conveniences stores, previously only available at pharmacies, beginning July 21, but consumers found that companies need more time to allow for the expanded distribution and manufacturing
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.